BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 21630274)

  • 21. [A special uterine leiomyoma].
    Brunet A; Verkarre V; Le Frère Belda MA
    Ann Pathol; 2020 Apr; 40(2):180-184. PubMed ID: 32192807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
    Ooi A
    Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased risk of cancer in patients with fumarate hydratase germline mutation.
    Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
    J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues.
    Maxwell PH
    J Pathol; 2011 Sep; 225(1):1-3. PubMed ID: 21792933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas.
    Ahvenainen T; Kaukomaa J; Kämpjärvi K; Uimari O; Ahtikoski A; Mäkinen N; Heikinheimo O; Aaltonen LA; Karhu A; Bützow R; Vahteristo P
    Am J Surg Pathol; 2022 Apr; 46(4):537-546. PubMed ID: 34678832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
    Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
    Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
    Harrison WJ; Andrici J; Maclean F; Madadi-Ghahan R; Farzin M; Sioson L; Toon CW; Clarkson A; Watson N; Pickett J; Field M; Crook A; Tucker K; Goodwin A; Anderson L; Srinivasan B; Grossmann P; Martinek P; Ondič O; Hes O; Trpkov K; Clifton-Bligh RJ; Dwight T; Gill AJ
    Am J Surg Pathol; 2016 May; 40(5):599-607. PubMed ID: 26574848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
    Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
    Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
    Plevová P; Hladíková A; Tesařová M
    Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes.
    Carter CS; Skala SL; Chinnaiyan AM; McHugh JB; Siddiqui J; Cao X; Dhanasekaran SM; Fullen DR; Lagstein A; Chan MP; Mehra R
    Am J Surg Pathol; 2017 Jun; 41(6):801-809. PubMed ID: 28288038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
    Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
    Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
    Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
    Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations.
    Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O
    Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
    Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
    Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses.
    El-Zaatari Z; Divatia MK
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S7-S17. PubMed ID: 32108620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
    Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
    J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.